Friedrich Overkamp

2.9k total citations
64 papers, 592 citations indexed

About

Friedrich Overkamp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Friedrich Overkamp has authored 64 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Friedrich Overkamp's work include Advanced Breast Cancer Therapies (25 papers), Cancer Genomics and Diagnostics (16 papers) and HER2/EGFR in Cancer Research (15 papers). Friedrich Overkamp is often cited by papers focused on Advanced Breast Cancer Therapies (25 papers), Cancer Genomics and Diagnostics (16 papers) and HER2/EGFR in Cancer Research (15 papers). Friedrich Overkamp collaborates with scholars based in Germany, United States and Estonia. Friedrich Overkamp's co-authors include Diana Lüftner, Dirk Strumberg, Johannes Ettl, Tanja Fehm, Andreas Schneeweiß, Peter A. Fasching, D. Wallwiener, Wolfgang Janni, Michael P. Lux and K. D. Bock and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Friedrich Overkamp

62 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Friedrich Overkamp Germany 13 356 206 204 149 57 64 592
Laurence Vanlemmens France 15 675 1.9× 244 1.2× 198 1.0× 169 1.1× 48 0.8× 70 961
Pauline de Graeff Netherlands 17 262 0.7× 138 0.7× 131 0.6× 257 1.7× 73 1.3× 36 763
Fernando Franco Spain 14 305 0.9× 235 1.1× 211 1.0× 215 1.4× 71 1.2× 44 803
Rossana Ruiz Peru 14 391 1.1× 134 0.7× 256 1.3× 228 1.5× 46 0.8× 47 718
Weijiang Liang China 12 357 1.0× 145 0.7× 105 0.5× 175 1.2× 82 1.4× 23 639
Hye Sook Han South Korea 19 352 1.0× 138 0.7× 258 1.3× 229 1.5× 141 2.5× 72 789
Harlinde De Schutter Belgium 16 428 1.2× 177 0.9× 181 0.9× 79 0.5× 165 2.9× 52 752
Katherine Enright Canada 10 412 1.2× 216 1.0× 138 0.7× 119 0.8× 16 0.3× 36 627
Reuben Broom New Zealand 14 445 1.3× 242 1.2× 271 1.3× 120 0.8× 168 2.9× 35 780
Grenville Oades United Kingdom 13 314 0.9× 105 0.5× 316 1.5× 231 1.6× 68 1.2× 30 653

Countries citing papers authored by Friedrich Overkamp

Since Specialization
Citations

This map shows the geographic impact of Friedrich Overkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Friedrich Overkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Friedrich Overkamp more than expected).

Fields of papers citing papers by Friedrich Overkamp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Friedrich Overkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Friedrich Overkamp. The network helps show where Friedrich Overkamp may publish in the future.

Co-authorship network of co-authors of Friedrich Overkamp

This figure shows the co-authorship network connecting the top 25 collaborators of Friedrich Overkamp. A scholar is included among the top collaborators of Friedrich Overkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Friedrich Overkamp. Friedrich Overkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lüftner, Diana, Andreas Hartkopf, Michael P. Lux, et al.. (2021). Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. Breast Care. 16(2). 108–114. 3 indexed citations
2.
Hartkopf, Andreas D., Volkmar Müller, Achim Wöckel, et al.. (2019). Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe und Frauenheilkunde. 79(3). 256–267. 12 indexed citations
3.
4.
Decker, Thomas, Friedrich Overkamp, Siegfried Rösel, et al.. (2017). A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). BMC Cancer. 17(1). 499–499. 22 indexed citations
5.
Staehler, Michael, et al.. (2017). Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma: Data from the German prospective RCC-Registry. Annals of Oncology. 28. v322–v322. 1 indexed citations
6.
Untch, Michael, Doris Augustin, Johannes Ettl, et al.. (2016). ABC3 Consensus Commented from the Perspective of the German Guidelines. Geburtshilfe und Frauenheilkunde. 76(2). 156–163. 7 indexed citations
7.
Thomssen, Christoph, Doris Augustin, Johannes Ettl, et al.. (2016). ABC3 Consensus: Assessment by a German Group of Experts. Breast Care. 11(1). 61–70. 7 indexed citations
8.
Fasching, Peter A., Sara Y. Brucker, Tanja Fehm, et al.. (2015). Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. Geburtshilfe und Frauenheilkunde. 75(1). 41–50. 43 indexed citations
9.
Overkamp, Friedrich, et al.. (2013). Das ökonomische Dilemma. Oncology Research and Treatment. 36(Suppl. 2). 41–44. 3 indexed citations
10.
Overkamp, Friedrich, et al.. (2013). (Fehl-)Steuerung im Gesundheitswesen. Oncology Research and Treatment. 36(Suppl. 5). 20–27. 1 indexed citations
11.
12.
Wörmann, Bernhard, Mathias Freund, Friedrich Overkamp, & Gerhard Ehninger. (2013). Klinische Studien in der Onkologie - 2013 und zukünftig. Oncology Research and Treatment. 36(Suppl. 2). 3–8. 3 indexed citations
13.
Horneber, Markus, Friedrich Overkamp, & Matthias Rostock. (2012). Umsetzung integrativer Konzepte eine Bestandsaufnahme. Onkologie. 35(s5). 3–11. 4 indexed citations
14.
Herrmann, Eva, Norbert Marschner, Marc‐Oliver Grimm, et al.. (2011). Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World Journal of Urology. 29(3). 361–366. 23 indexed citations
15.
Kirchner, Hartmut, Dirk Strumberg, Amit Bahl, & Friedrich Overkamp. (2010). Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy. 10(4). 585–596. 20 indexed citations
16.
Knauf, Wolfgang, Burkhard Otremba, Friedrich Overkamp, & Martin Kornacker. (2009). Bortezomib in Relapsed Multiple Myeloma – Results of a Non-Interventional Study by Office-Based Haematologists. Oncology Research and Treatment. 32(4). 175–180. 3 indexed citations
17.
Jackisch, Christian, Michael Untch, Friedrich Overkamp, et al.. (2008). Adherence to Treatment Guidelines in Breast Cancer Care – a Retrospective Analysis of the ‘Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie’. Breast Care. 3(2). 87–92. 10 indexed citations
18.
Oskay-Özcelik, Gülten, Walter Lehmacher, Dominique Könsgen, et al.. (2007). Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients. Annals of Oncology. 18(3). 479–484. 76 indexed citations
19.
Jackisch, Christian, Michael Untch, Friedrich Overkamp, et al.. (2006). Das Mammakarzinom: Versorgungslage und Therapiequalität in Deutschland 2004. Zentralblatt für Gynäkologie. 128(6). 352–361. 2 indexed citations
20.
Höffken, K., Friedrich Overkamp, Axel Grothey, et al.. (1990). Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor and Low-Dose Cytosine-Arabinoside in the Treatment of Patients with Myelodysplastic Syndromes. Oncology Research and Treatment. 13(1). 33–37. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurence Vanlemmens Breakdown of academic impact, for papers by Pauline de Graeff Breakdown of academic impact, for papers by Fernando Franco Breakdown of academic impact, for papers by Rossana Ruiz Breakdown of academic impact, for papers by Weijiang Liang Breakdown of academic impact, for papers by Hye Sook Han Breakdown of academic impact, for papers by Harlinde De Schutter Breakdown of academic impact, for papers by Katherine Enright Breakdown of academic impact, for papers by Reuben Broom Breakdown of academic impact, for papers by Grenville Oades
Rankless by CCL
2026